alexa Natural Killer Cell Subsets Distribution in Spontaneously Resolved and Chronic Persistent Hepatitis C Virus Infection | Open Access Journals
ISSN: 2155-9899
Journal of Clinical & Cellular Immunology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Natural Killer Cell Subsets Distribution in Spontaneously Resolved and Chronic Persistent Hepatitis C Virus Infection

Laila M Al Kady1, Marwa A Mansour1*, Samaa T Gobran1 and Ebtesam I Ahmad2

1Medical Microbiology and Immunology Department, Faculty of Medicine, Zagazig University, Egypt

2Clinical Pathology, Faculty of Medicine, Zagazig University, Egypt

*Corresponding Author:
Marwa Abd El Azim Mansour
Associate Professor of Medical Microbiology and Immunology
Faculty of Medicine, Zagazig University, Egypt
E-mail: [email protected]

Received date: March 29, 2017; Accepted date: May 09, 2017; Published date: May 22, 2017

Citation: Kady LMA, Mansour MA, Gobran ST, Ahmad EI (2017) Natural Killer Cell Subsets Distribution in Spontaneously Resolved and Chronic Persistent Hepatitis C Virus Infection. J Clin Cell Immunol 8:504. doi: 10.4172/2155-9899.1000504

Copyright: © 2017 Kady LMA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Clinical & Cellular Immunology

Abstract

Altered natural killer cell subsets frequency and distribution have been reported in Hepatitis C Virus (HCV) infection. Aim of the work was to study the frequency of the NK cells and distribution of their subsets in spontaneously resolved (SR) and chronic persistent Hepatitis C Virus (CHC) infection. In addition, to study the frequency of inhibitory receptor CD158b in these clinical outcomes and to correlate its frequency with certain clinical and diagnostic parameters. This study was conducted on 48 patients divided into 3 groups. Group I; 16 chronic persistent HCV patients, Group II; 16 SR individuals and Group III; 16 healthy controls. Chronic persistent HCV patients and SR individual’s data were reported from patients' reports. Healthy controls serum antibodies against HCV were measured using ELISA technique. The three studied group’s fresh peripheral blood samples were analyzed by flow cytometry to determine total NK cells, CD56+dim CD16+, CD56+bright CD16- NK cell percentages and CD158b frequency. Total NK cells and CD56+dim CD16+ NK cells were decreased significantly in chronic persistent HCV patients and SR individuals in comparison to healthy controls (P<0.001). CD56+bright CD16- NK cells were significantly expanded in CHC patients in comparison with healthy controls (P<0.001), while their significant reduction was noticed in SR individuals in comparison with healthy controls (P<0.001). Significant elevation of CD158b inhibitory receptor frequency in CHC patients in comparison with healthy controls (P<0.001), while no significant elevation was noticed in SR individuals (P>0.05). Positive correlation between CD158b frequency and cirrhosis, unresponsiveness to IFN, WBCs and lymphocytes counts and AST and ALT levels in CHC patients was observed. However, there was negative correlation between it and total protein. Moreover, no correlation between CD158b frequency and viral load was detected in CHC patients. In conclusion, during the chronic HCV infection stage, the antiviral activity of NK cells is significantly depressed. The NK cell function was impaired and conferred inhibitory signals. There were total NK cells and CD56+dim CD16+ NK cells reduction, CD56+bright CD16- NK cells expansion and elevated CD158b inhibitory receptor representing this impairment. On the other hand, in SR individuals, total NK cells were significantly decreased. Also, CD56+dim CD16+ NK cells and CD56+bright CD16- NK cells percentages were significantly decreased (P<0.001) although preserving nearly the same ratio of healthy controls. Also, there was no significant elevation in CD158b frequency (P>0.05).

Keywords

Global Fund’s support; HIV/AIDS; Thailand; Transition

Introduction

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. The long-term impact of chronic persistent HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma [1].

Natural killer (NK) cells are large granular lymphocytes that account for the majority of innate immune cells in the human liver. They play an important role in the control of viral infections. Their functions are mediated by a diverse array of inhibitory and activating cell-surface receptors [2].

In human peripheral blood, the CD3-NK cells are divided into five subpopulations which can be defined on the basis of the relative expression of the markers CD16 (Fc γ RIII) and CD56:CD56 dim CD16+, CD56 dim CD16-, CD56 bright CD16, CD56 bright CD16+, and CD56CD16+ [3].

CD56+dim CD16+ NK cells normally account approximately 90% of peripheral NK cells. They usually express CD16 which is the Fc receptor for IgG, killer cell immunoglobulin-like receptors (KIRs) and homing markers for inflamed peripheral sites. They carry perforin, and are the main mediators of NK cytotoxicity [4].

CD56+bright CD16NK cells account nearly 10% of peripheral NK cells. They express homing markers for secondary lymphoid tissues where they accumulate. They do not express KIRs, contain low levels of perforin, and are only weakly cytotoxic. However, they are important secretors of cytokines including IFN-gamma, TNF-α, granulocyte-macrophage colony-stimulating factor (GMCSF), interleukin 10 (IL10) and IL13 [5].

Most prominent among NK receptors are the killer cell immunoglobulin-like receptors (KIRs). CD158b is one of KIRs which confers inhibitory signals to NK cells leading to their suppression [6].

In chronic persistent HCV infection, NK cells display alterations in their phenotype and function. Furthermore, cytolytic NK cells seem to be impaired through high expression of inhibitory receptors including CD 158b [7].

On the other hand, CD158b low frequency seems to predict resolution of chronic persistent HCV infection. Also, CD158b may correlate with some diagnostic parameters in chronic HCV patients [8]. On contrary, in spontaneously resolved HCV infection, the activated NK cells' responses suggest an important contribution to resolution of the infection, as there is a good cytolytic function of NK cell and normal expression of inhibitory cell surface receptors [9].

Material and Methods

Study design

This case control study was conducted in Medical Microbiology and Immunology Department and Clinical pathology Department, Faculty of medicine, Zagazig University during the period from June 2014 to December 2015.

Ethical considerations

Approval for performing this study was obtained from Microbiology and Immunology Department and Clinical Pathology Department after taking Institutional Review Board (IRB) and ethical committee approval. Also, written informed consent was obtained from each participant.

Subjects

The study included 48 subjects from both sexes.

Inclusion criteria

Group (I): They were 16 chronic persistent HCV infection patients.

They were anti-HCV antibody positive and had detectable serum level of HCV RNA by PCR for at least 6 months [10].

Group (II): It included 16 spontaneously resolved (SR) individuals. Those individuals were attending the outpatient clinic of Tropical Medicine Department, Zagazig University Hospitals. They were anti-HCV antibody positive and had detectable serum level of HCV RNA by PCR. They discovered HCV clearance accidentally while performing pre-treatment investigations including PCR which revealed negative result. They were retested again for serum HCV RNA by PCR after 12 weeks for confirmation of resolution and exclusion from treatment regimen [11].

Group (III): They were 16 apparently healthy individuals, proved to be negative for HCV Abs by ELISA and had no history of liver diseases.

Exclusion criteria for the three groups

Individuals with history of or had current HBV or HIV infections were excluded. In addition, individuals who had autoimmune hepatitis, metabolic liver disease, history of exposure to hepatotoxin or immuno-suppressive therapy were also excluded.

Data collection

1. Age and sex for all groups.

2. Other data

Clinical data including ascitis, jaundice and cirrhosis of variable degrees were reported from patients' files. Recent history of interferon treatment, results:

For group (I): HCV Ab by ELISA and HCV RNA by PCR were also reported from patients' files.

For group (II): Previous and recent results of HCV Ab by ELISA, HCV RNA by PCR as well as routine laboratory investigations done in Clinical Pathology Department were taken from patients' files.

Sampling

Fresh blood sample (5 ml) was collected under routine aseptic condition from all members included in the study. Serum was separated and divided in three tubes. One tube was used for routine laboratory investigations and the second one was stored at -20°C for HCV Ab detection using ELISA assay (Axiom, Worms (WO), Germany). The third sample was taken in a sterilized tube containing EDTA, which was transported immediately to laboratory for flow cytometric analysis. Samples with hemolysis, clots or suspended cell aggregates were discarded.

Sample preparation and flow cytometric analysis: Peripheral blood mononuclear cells (PBMCs) were purified using whole blood lysis technique [12]. Cellsurface staining was performed using mouse anti-human monoclonal antibodies (mAbs), anti-CD3 fluorescein isothiocyanate, anti-CD16peridinin chlorophyll protein conjugate, anti-CD56 phycoerythrin conjugate (PE) and CD158b monoclonal antibody labeled with FITC (BD Biosciences, San Diego, USA).

Staining was performed by adding 20 μL of each mAb to 100 μL of blood, followed by incubation for 30 minutes in the dark at 4°C. The tubes were washed twice with FACs buffer. Erythrocytes were lysed using BD FACS lysing Solution (BD Biosciences, San Diego, USA). Finally, 0.5 mL of phosphate buffered saline was added to the washed cells prior to measurement of CD3-CD16+CD56+ cells. We used appropriate isotype controls of anti-human mAbs to prevent nonspecific Fc receptor staining. Sample analysis was performed with a FACSCalibur flow cytometer (Becton Dickinson, San Jose, California, USA). FACs-acquisition and analysis were performed with FACs Cell Quest software (BD Biosciences, San Diego, USA). Samples were first examined for the frequency of CD3- CD16+CD56+ NK cells. The percentages of CD158 cells in the total NK cell population were then determined.

Statistical analysis

The collected data were computerized and statistically analyzed using SPSS program (Statistical Package for Social Science) version 18.0. Qualitative data were represented as frequencies and relative percentages. Chi square test was used to calculate difference between qualitative variables. Quantitative data were expressed as mean ± SD (Standard deviation). Independent T test was used to calculate difference between quantitative variables in two groups. ANOVA F-test test was used to calculate difference between quantitative variables in more than two groups. KruskalWallistest (K) was used to calculate difference between quantitative variables in more than 2 groups in not normally distributed data. Pearson correlation coefficient used to calculate correlation between quantitative variables. The significance Level for all above mentioned statistical tests done. The threshold of significance is fixed at 5% level (P-value). P value of >0.05 indicates non-significant results while that of <0.05 indicates significant results.

Results

This study was conducted on 3 groups; group (I) included 16 chronic persistent HCV infection patients. They were 9 males and 7 females, the ages ranged from 18 to 65 years old (Mean ± SD: 38.88 ± 14.89), group (II): It consisted of 16 SR individuals. They were 9 males and 7 females, their ages ranged from 18 to 65 years old (Mean ± SD: 38.63 ± 14.22) and group (III): It included 16 healthy controls. They were 13 males and 3 females, their ages ranged from 19 to 55 years old (Mean ± SD: 37.06 ± 11.69).There were no statistical significance differences between the three studied groups as regards age (P>0.05) and sex (P>0.05) distributions (data not shown).

There were statistically significant reduction in the total NK cells among chronic HCV patients and SR patients compared to healthy controls, (P<0.001). There were no statistically significant differences between the two patient groups (P>0.05). On the other hand, there were statistical significance reduction in CD56+dim CD16+ NK cells percentages among chronic HCV cases compared to SR individuals and healthy controls, (P<0.001). As regards the CD56+bright CD16- NK cells percentage, it was significantly expanded in chronic HCV cases compared with healthy controls, (P<0.001) while it was significantly reduced in the SR group compared to the control group, (P<0.001) (Table 1, Figures 1 and 2).

clinical-cellular-immunology-Total-NK

Figure 1: Total NK cells, CD56+dim CD16+, CD56+brightCD16 cells in the three studied groups.

clinical-cellular-immunology-Flow-cytometry

Figure 2: Flow cytometry analysis for the percentage of natural killers. Peripheral blood mononuclear cells were stained for CD3, CD16, CD56 cells of the gated lymphocytes populations, with exclusion of dead cells. A: CD56 Expression with setting of CD3-/CD56brightand CD56dim cells. B: shows CD3-/CD16+cells.

Variable Chronic HCV(n=16) Spontaneous resolved (n=16) Control(n=16) Test p LSD
Total NK           <0.001*1
Mean ± SD 11.84 ± 0.24 11.88 ± 0.26 22.2 ±7.45 30.72 <0.001** <0.001*2
Range (%) 11.5-12.3 11.5-12.3 19.8-50.05     0.98 3
CD56+dim CD16+           <0.001*1
NK cells:            
Mean ± SD 7.41 ± 0.18 10.68 ± 0.23 18.42 ±0.39 646.2 <0.001* <0.001*2
Range (%)* 7.07-7.75 10.23-11 17.86-18.9     <0.001*3
 CD56+brightCD16−           <0.001*1
 NK cells:            
Mean ± SD 4.28 ± 0.91 1.12 ± 0.08 1.6 ± 0.56 396.5 <0.001* <0.001*2
Range (%)* 3.9-4.6 1-1.23 1.03-2.8     <0.001*3

Table 1: Flow cytometeric analysis of NK cell subsets in the three studied groups; Control versus Chronic HCV, Control versus Spontaneous resolved, Chronic HCV versus spontaneous resolved. (%): percentage of total NK cell count to the total lymphocytic count. (%)*: percentage of CD56+dim CD16+NK cells and CD56+brightCD16-NK cells count to the total NK cell count.

Concerning CD158b inhibitory receptor, there were significant elevations in its frequency among chronic persistent HCV patients compared to SR group and healthy controls (P<0.001), while no significant difference was found in spontaneously resolved individuals compared to the control group (P>0.05) (Table 2 and Figure 3). We found no statistical significant correlation between CD158b level among the three groups and total NK cell, CD56+dim CD16+ cells nor CD56+bright CD16- cells percentages (data not shown).

clinical-cellular-immunology-natural-killer

Figure 3: Flow cytometry analysis for the percentage of CD158 expression on the natural killer cells among the three studied groups. Peripheral blood mononuclear cells were stained for CD3, CD16, CD56 cells of the gated lymphocytes populations, with exclusion of dead cells. Then CD158 percentage was measured among it.

  Chronic Spontaneous Control Test F P LSD
  HCV (n=16) resolved (n=16) (n=16)      
CD 158 b:           <0.001*1
Mean ± SD 7.32 ± 1.67 0.02 ± 0.02 0.02 ± 0.02 K <0.001** 0.992
Range (%) 5-9.3 0-0.05 0-0.06 31.75   <0.001*3

Table 2: CD158b frequency in the three studied groups. 1Control versus Chronic HCV, 2Control versus spontaneous resolved, 3Chronic HCV versus spontaneous resolved.

There was a statistical significance correlation between CD158b and severity of cirrhosis and response to interferon (P<0.001) with increase of its level among severe cirrhotic cases and non-responder cases. Furthermore, a significant positive correlation was found between it versus WBCs and lymphocytes counts and AST and ALT levels in chronic HCV patients. However, there was negative correlation between it and total protein. Also, there was no correlation between it and viral load in chronic HCV patients (Tables 3 and 4).

Variable N CD 158 b mean ± SD Test P
Cirrhosis:        
No 7 5.57 ± 0.47 T 12.21 <0.001**
Severe 9 8.68 ± 0.54    
Ascites:        
No 12 7.36 ± 1.62    
        0.56
Mild 1 9.1 ± 0.00 F 0.72 NS
Moderate 2 7.08 ± 2.5    
Severe 1 5.56 ± 0.00    
Jaundice:        
No 11 7.86 ± 1.47 t 2.11 0.06
Yes 5 6.14 ± 1.59   NS
Response to interferon:        
No clearance 5 8.9 ± 0.61    
Partial clearance 4 8.51 ± 0.46 F 77.03 <0.001**
Complete clearance 7 5.57 ± 0.47    
Viral load (PCR):        
Mild viremia 4 7.26 ± 1.72    
      F 0.27 0.77
Moderate viremia 7 7.65 ± 1.87   NS
Severe viremia 5 6.90 ± 1.62    

Table 3: Correlation between CD 158b frequency and certain clinical data, response to interferon and viral load in chronic HCV group.

Variable CD158b          
  Spontaneous          
  Chronic HCV(n=16)   resolved(n=16)   Control  
  r P r P r P
WBCs (x103/mm3): 0.9 <0.001* 0.28 0.29 -0.51 0.06
Lymphocyte (%): 0.83 <0.001* 0.17 0.54 -0.03 0.91
Total Bilirubin (mg/dL): -0.23 0.4 0.13 0.11 -0.21 0.31
Direct Bilirubin (mg/dL): -0.06 0.83 0.32 0.12 -0.22 0.32
AST (IU/L): 0.98 <0.001* -0.07 0.81 0.003 0.99
ALT (IU/L): 0.93 <0.001* 0.05 0.85 0.08 0.77
Total protein (g/dL): -0.58 0.02* -0.24 0.38 0.1 0.71
Albumin (g/dL): -0.42 0.1 0.41 0.12 -0.22 0.41

Table 4: Correlation between CD158b frequency and certain routine laboratory investigations in the three groups.

Discussion

In our study, the percentage of total NK cells was shown to be decreased significantly in chronic HCV patients and spontaneously resolved individuals compared to their levels in healthy controls. However, no significant differences were found between their levels between spontaneously resolved individuals and chronic HCV patients. This observation was consistent with Morishima et al. [13], Bonorino et al. [14] and Dessouki [15].

This could be explained by Meier [16] who suggested that the deficit in interleukin 15 (IL-15) might be responsible for this change. It is thought that IL15 regulates the function of NK cells and promotes their survival.

On contrary, others like Nattermann et al. [17] noticed no differences in NK total cell count between HCV infected individuals and healthy controls. On the other hand, Dessouki [15] reported that spontaneous resolvers and healthy controls showed the same total NK cell frequency.

The diversity of observations in the above-mentioned studies regarding NK frequency is likely to be due to heterogeneity of patients, diversity of HCV subtypes and viral loads, variations in the duration of HCV infection and the presence of other microbial infections [16].

We demonstrated that CD56+dim CD16+ was lower in HCV-infected patients compared with healthy controls and resolvers. This agreed with Morishima et al. [13] and Lee et al. [18]. Although this disagreed with some studies such as Nattermann et al. [17] and De Maria et al. [19] who reported no significant reductions in NK cytolytic activity in patients with chronic HCV infection. The difference is likely to be due to pathogen-associated factors such as diversity of HCV viral quasispecies and HCV genotype [20]. In our study we noticed an expansion in CD56+bright CD16 NK cells in chronic HCV patients compared to healthy controls and spontaneously resolved individuals. This result was consistent with Ferlazzo et al. [21], Dessouki et al. [15] and Jost et al. [22].

Jost et al. [22] mentioned that altered NK cell subset distributions are unlikely to be due to selective sequestration in the liver because NK cells are not expanded in HCV-infected livers only and their numbers in blood positively correlated with those in liver.

Alternatively, Chan et al. [23] suggested that the altered NK cell subset distributions in persistently infected patients could be the result of decreased rates of differentiation of CD56+brightCD16NK cells into CD56+dim CD16+ NK cells.

On contrast to all previous studies, Hui-Fan et al. [8] noticed no significant changes in the CD56+dimCD16+ NK cell and CD56+bright CD16 NK cell levels in chronic HCV patients in comparison with healthy controls and spontaneously resolved individuals.

By analyzing the NK cell phenotypes after HCV infection, we found that the high expression levels of CD158b (KIR2DL3) were only present in individuals with chronic HCV infections while its expression in spontaneously resolved individuals was very low similar to expression levels in healthy controls. This data indicated that the increased number of inhibitory receptors present on NK cells suppresses NK cell activation and this agreed with Khakooet al. [24] and Knapp et al. [25].

Furthermore, we analyzed the relationship between CD158b and the degree of cirrhosis. We noticed a positive correlation between CD158b and degree of cirrhosis. This agreed with Hui-Fan et al. [8] and Bin and Svetlana [26] who hypothesized that high expression level of this receptor on NK cells interfered with the development of an immune response and associated with HCV immune escape. These persistently weak immune responses resulted in liver cell destruction and cirrhosis.

On contrary, lee and co-workers, [18] mentioned that low NK cell cytotoxicity by CD158b limits liver damage and fibrosis.

Regarding the response of the chronic HCV patients to interferon (IFN), we observed that patients with high CD158b expression are unresponsive to IFN therapy. This is consistent with Golden-Mason et al. [27,28] and Hui-Fan et al. [8].

Also, we found no correlation between CD158b on NK cells and serum HCV RNA loads in chronic HCV patients. This result is consistent with Hui-Fan et al. [8].

We further analyzed the role of altered CD158b expression patterns on NK cells in relation to chronic HCV pathogenesis. Correlation analysis revealed that the percentage of CD158b+ NK cells significantly

positively correlated with serum AST and ALT levels in chronic HCV patients. This agreed with Vidal-Castineira et al. [10] and Hui-Fan et al. [8]. The later explained that the impaired immune response caused by CD158b leads to exaggerated hepatocytes damage by HCV with high liver enzymes.

As regards other clinical data such as ascitis, jaundice and other diagnostic laboratory parameters such as total, direct bilirubin and albumin, there was no significant correlation between them and CD158b in our study. No other reports showing significant correlation were found.

Conclusion

We found that during the chronic HCV infection stage, there were reduction in the total NK and CD56+dim CD16+ NK cells. While there was expanded CD158b+ population among the chronic HCV group with absence of this finding among the SR group. A positive correlation were found between CD158b+ with both AST and ALT levels among the chronic HCV and SR while no correlation was detected between CD158b and viral load. Finally, we concluded that the antiviral activity of NK cells is significantly depressed among the chronic HCV patients and the antiviral activity of NK cell function was significantly depressed with inhibitory signals.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 347
  • [From(publication date):
    June-2017 - Sep 26, 2017]
  • Breakdown by view type
  • HTML page views : 306
  • PDF downloads :41
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords